Changes

==Gene Overview==

==Gene Overview==

The protein encoded by RUNX1 can bind the protein encoded by CBFB to form "Core Binding Factor", a hetero-dimeric transcription factor, which regulates a number of genes responsible for hematopoiesis  and osteogenesis (2).  Runx1 protein can bind to DNA as a monomer through the Runt domain within the Runx1 protein.  The RUNX1 gene is the most frequent target for chromosomal translocation in leukemia (1). Alterations of RUNX1 are typically loss of function or decreased function, and  are considered "secondary driver mutations" (disease progression) in sporadic leukemias (2), but germline RUNX1 mutations contribute a lifetime risk of myeloid malignancy of about 44% (2).  RUNX1 mutations (loss of function or decreased function) have been associated with decreased P53 activity and increased DNA repair defects and increased inflammation (2).  RUNX1 mutations are associated with gene mutations in ASXL1, MLLPTD, and IDH1/IDH2, but  and are mutually exclusive with NPM1 mutations (3).   Non-complex RUNX1 mutations were found to be associated with resistance to chemotherapy, and decreased disease free survival (DFS), event free survival (EFS) and overall survival (OS) (3). More importantly, RUNX1 mutations were deemed to be an independent prognostic marker for shorter EFS in multivariable analysis [62].  

The protein encoded by ''RUNX1'' can bind the protein encoded by ''CBFB'' to form "Core Binding Factor", a hetero-dimeric transcription factor which regulates a number of genes responsible for hematopoiesis  and osteogenesis [2].  Runx1 protein can bind to DNA as a monomer through the Runt domain within the Runx1 protein.  ''RUNX1'' is the most frequent target for chromosomal translocation in leukemia [1]. Alterations of ''RUNX1'' are typically loss of function or decreased function, and  are considered "secondary driver mutations" (disease progression) in sporadic leukemias [2], but germline ''RUNX1'' mutations contribute a lifetime risk of myeloid malignancy of about 44% [2].  ''RUNX1'' mutations (loss of function or decreased function) have been associated with decreased P53 activity and increased DNA repair defects and increased inflammation [2].  ''RUNX1'' mutations are associated with gene mutations in ''ASXL1'', ''MLLPTD'', and ''IDH1''/''IDH2'', but  and are mutually exclusive with ''NPM1'' mutations [3]. Non-complex ''RUNX1'' mutations were found to be associated with resistance to chemotherapy, and decreased disease free survival (DFS), event free survival (EFS) and overall survival (OS) [3]. More importantly, ''RUNX1'' mutations were deemed to be an independent prognostic marker for shorter EFS in multivariable analysis [62].

==Common Alteration Types==

==Common Alteration Types==